We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -6.06% | 0.775 | 0.75 | 0.80 | 0.825 | 0.775 | 0.83 | 611,345 | 15:32:48 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.35 | 1.39M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/8/2018 08:00 | OneDayRodders, the objective for the derampers is to discredit me and everything I say, In that instance saying nothing is no defence. At the end of the day it is this board that suffers. Lewis, I think I have proved that your hatred of me started from your very first posts on N4. You have destroyed this BB quite enough with your vendetta. | hughwilson | |
08/8/2018 07:48 | The share price would suggest not, at least not without a substantial fund raise to go round the houses again. | rathean | |
07/8/2018 16:54 | Oh and thanks for your little curation of my old posts earlier. I'm glad I found you out as far back as May - quite enjoyed the "gallantly talking to himself on Twitter and suggesting Pfizer would be fools not to do a JV" one.. it's like you were you trying to jog everyone's memory as to how wrong you have been. | dplewis1 | |
07/8/2018 15:12 | LOL. I thought the N4P reformulated sildenafil was going to take all the market... You are arguing against yourself. If you say that the generics are going to win, there will be no room for an expensive debatably beneficial alternative. I have been completely consistent in what I have written. Go back and point out where I said the opposite about generics. Some times I lose the will to live... | nobbygnome | |
07/8/2018 15:10 | And before anyone says anything, N4`s patent covers them for India too. | hughwilson | |
07/8/2018 14:58 | Nobby, "The generics will win the vast majority of the market based on price, which will be absolutely no surprise to Pfizer. Viagra Connect was part of the defence but ultimately will only delay the inevitable." That is EXACTLY what I have been saying this last few months while you have been saying the opposite. Glad that you finally agree. | hughwilson | |
07/8/2018 14:45 | You are showing your naivety again hugh. Pfizer will have been preparing for this for years as all Pharma companies have to manage the appearance of generic competition. This does not mean that they will buy a new version which has questionable advantages. The generics will win the vast majority of the market based on price, which will be absolutely no surprise to Pfizer. Viagra Connect was part of the defence but ultimately will only delay the inevitable. Your posts are so misleading and I am sure newbys here may well have been taken in by your misinformation. | nobbygnome | |
07/8/2018 06:44 | Well I'm glad you have finally understood something Hugh - I think you are a highly untrustworthy individual and also a fraud. I have also developed a personal dislike of you because of your lack of humility and refusal to accept that your posts about N4 were misleading and harmful. If your contribution to the board has been to post unsubstantiated ramps then it has been mine to question those posts. In return you have not argued your case but have instead resorted to angry and aggressive outbursts that have further debased your position. | dplewis1 | |
07/8/2018 00:25 | Lewis, I also said that a deramper will attack and try to discredit anyone who says anything positive. I invite people to have a look at your N4 posting history, from your very first post on N4 virtually all of your posts have been personal attacks on my person in an effort to try and discredit me. No point in denying that as people only have to take a look, and before you talk about my attacks on you, your attacks on me started a long long time before I stopped treating you with respect. | hughwilson | |
07/8/2018 00:18 | Nobby, you seem to delight in slagging Nigel off. Makes me wonder why you are an investor but of course you`re not are you. Also, Nuvec is being positioned to become the industry standard as I proved to you in an earlier post. In that instance the probability is that Nuvec would indeed be huge. | hughwilson | |
06/8/2018 15:01 | LOL talking about frauds, it takes one to know one! I think you could say the same about your beloved Nigel as well... | nobbygnome | |
06/8/2018 14:10 | Talking about yourself in the third person isn't doing you any favours Hugh. For the record I have never 'trash talked' N4 nor any other share, I have merely expressed an opinion. I have also never shorted a stock for my personal account. What is amusing to me is that you say 'derampers' use fear as a weapon, but you fail to acknowledge that you use greed as your primary instrument. Comments such as 'the probability is that Nuvec will be huge' are surely just the opposite side of an unsubstantiated negative post. You are the yin to a derampers yang and are just as guilty of spreading misinformation as the people you so vilify. | dplewis1 | |
06/8/2018 08:57 | DOWN,!!!!!! | escapetohome | |
06/8/2018 08:57 | Hugh has lost the plot!!! | eddie_yates | |
06/8/2018 08:57 | I think that could be optimistic ken. I may buy back sub 5p. | escapetohome | |
05/8/2018 19:14 | If you win - glory If you fail - its the dog house for you. N4p rns was unacceptable. Im not not short, but there are no n4p shares in my dealing account. Didnt make the fortune i hoped for, but didnt loose much either. The Astra “zenica” spelling mistake was when i realised hughwilson was a dubious, but and i just kept my involvement as few thousand gamble. | escapetohome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions